Barclays analyst Carter Gould raised the firm’s price target on Reata Pharmaceuticals to $110 from $98 and keeps an Overweight rating on the shares. The analyst says Skyclarus was approved ahead of schedule and the near-term focus will now be on start-form metrics and sales conversion.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RETA:
- Reata Pharmaceuticals gets approval of prior approval supplement for SKYCLARYS
- Short Report: Bears betting on stalled rebound for The Gap
- Reata Pharmaceuticals announces FDA filing acceptance of SKYCLARYS NDA
- Reata Pharmaceuticals names Rajiv Patni, M.D., as Chief R&D Officer
- 3 Best Stocks to Buy Now, 5/24/2023, According to Top Analysts